Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 50.30M | $184.0M | 9.42% | +7.11M | 2026-06-30 |
| ARK Investment Management LLC | 41.34M | $151.0M | 7.74% | +1.12M | 2026-06-30 |
| STATE STREET CORP | 34.71M | $127.0M | 6.50% | +6.22M | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 31.13M | $114.0M | 5.83% | +8.37M | 2026-06-30 |
| BAILLIE GIFFORD & CO | 23.49M | $86.0M | 4.40% | -187.5K | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 22.77M | $83.0M | 4.26% | +521.6K | 2026-06-30 |
| GEODE CAPITAL MANAGEMENT, LLC | 13.82M | $50.0M | 2.59% | +1.54M | 2026-06-30 |
| SOFTBANK GROUP CORP. | 13.64M | $50.0M | 2.55% | -- | 2026-06-30 |
| MIC Capital Management UK LLP | 9.64M | $35.0M | 1.81% | +1 | 2026-06-30 |
| UBS Group AG | 8.95M | $32.0M | 1.68% | +3.80M | 2026-06-30 |
